Physician profile
Heather Hilty
NPI 1619979135
$2,855.63
in general payments reported to CMS, 2019-2025
42 companies · $2,075 in 2025
The $2,075 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $89.30 · 2021: $135 · 2022: $69.53 · 2023: $108 · 2024: $36.58 · 2025: $2,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.66 |
| Education | $120.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $511.52 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $227.15 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $201.56 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| Incyte Corporation | $184.58 | 2025 | Monjuvi, Jakafi, Zynyz |
| Pfizer INC. | $168.77 | 2025 | |
| Abbvie INC. | $115.68 | 2025 | |
| Daiichi Sankyo INC. | $99.25 | 2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $92.66 | 2025 | Ojjaara, Jemperli |
| Astrazeneca Pharmaceuticals Lp | $91.54 | 2025 | Imfinzi, Lynparza, Calquence |
| Regeneron Healthcare Solutions, INC. | $87.62 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $76.20 | 2025 | |
| Beone Medicines USA, INC. | $74.63 | 2025 | Brukinsa, Tevimbra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.12 | 2023-2025 | Ofev |
| Beigene USA, INC. | $48.23 | 2025 | Brukinsa |
| Recordati_rare_diseases_inc. | $46.18 | 2025 | Enjaymo |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Hilty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.